John Lansing's Trending123
John Lansing's Trending123
Username: Password: Login
Trade Talk E-Letter Products & Services Trading Tools Portfolios Members Home

Stock Sectors

(Click sector to view stock chart)

Drugs - Generic

Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)


Caraco Pharmaceutical Laboratories, Ltd. engages in the development, manufacture, and marketing of generic, prescription, and over-the-counter pharmaceuticals in the United States. The company offers drugs relating to various therapeutic segments, such as central nervous system, cardiology, pain management, and diabetes. Its product portfolio comprises Metroprolol Tartrate for hyper-tension, Paromomycin Sulfate antibacterial product, Salsalate decongestant, CMT for Arthritis/NSAID, and Clonazepam for seizure and panic disorders. The company's portfolio also includes Flurbiprofen for Arthritis/NSAID, Carbamazepine for epilepsy, Oxaprozin for Rheumatoid disease, Metformin Hydrochloride for diabetes, Ticlopidine for reduction of incidence of strokes, and Digoxin for heart failure. As of March 31, 2005, its product portfolio comprised 17 prescription products in 36 strengths in 89 package sizes. Caraco Pharmaceutical markets it products through wholesalers, buying groups, retail pharmacies, and hospitals. The company was organized in 1984 and is based in Detroit, Michigan. Caraco Pharmaceutical Laboratories, Ltd. is a subsidiary of Sun Pharmaceutical Industries Limited.


Watson Pharmaceuticals, Inc. engages in the development, manufacture, marketing, distribution, and sale of branded and generic pharmaceutical products in the United States. It offers a range of generic products, such as antidepressants, anti-diabetics, analgesic, oral contraceptives, anti-hypertensives, anti-anxiety products, antibiotics, anti-infective systems, antihistamine products, and aid to smoking cessation. Watson Pharmaceuticals offers various branded pharmaceutical products that include specialty products, such as urology, anti-hypertensive, psychiatry, pain management, and dermatology products, as well as a genital warts treatment and a visual cervical screening device; and nephrology products, which consists of products for the treatment of iron deficiency anemia. The company sells its brand and generic pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including large chain drug stores, hospitals, and clinics; government agencies; and managed healthcare providers, such as health maintenance organizations and other institutions. Watson Pharmaceuticals was founded in 1983 and is headquartered in Corona, California.


Barr Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and marketing of pharmaceutical products. The company operates in two segments, Generic Pharmaceuticals and Proprietary Pharmaceuticals. The Generic Pharmaceuticals segment markets approximately 150 dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products, representing the category of its generic portfolio. It manufactures products in the form of tablets, capsules, and powder. The Proprietary Pharmaceuticals segment markets 13 proprietary pharmaceutical products, focusing in the female healthcare arena, including oral contraceptive and hormone therapy products; oncology; cardiovascular; anti-infective; and psychotherapeutic pharmaceuticals. These products include Aygestin, for amenorrhea; Cenestin line of hormone therapy products; Diamox and Sequels, for glaucoma; Loestrin/Loestrin Fe, and Nordette, for oral contraceptive; Plan B, for emergency oral contraceptive; Prefest, for hormone therapy; Revia, for alcohol dependence; SEASONALE, for extended-cycle oral contraceptive; Trexall, for rheumatoid arthritis; ViaSpan, for transplant preservation agent; and Zebeta and Ziac, for hypertension. Barr Pharmaceuticals markets its products to drug store chains, supermarket chains, mass merchandisers, wholesalers, distributors, managed care organizations, mail order accounts, government/military, and repackagers primarily in the United States and Puerto Rico. The company was founded by Edwin A. Cohen in 1970 and is headquartered in Woodcliff Lake, New Jersey.


Par Pharmaceutical Companies, Inc., a holding company, engages in the research, development, manufacture, and distribution of generic drugs in the United States. Its product line comprises generic prescription drugs consisting of 187 products representing various dosage strengths for 80 separate drugs. The company's generic drug products include central nervous system, cardiovascular, anti-inflammatory, gastrointestinal, and anti-infective treatments. Its products are manufactured principally in the solid oral dosage form consisting of tablets, caplets, and two-piece hard shell capsules. Par Pharmaceutical also distributes one oral suspension product and one product in the semisolid form of a cream. In addition, it designs and develops intermediate ingredients used in the production of finished products for the pharmaceutical industry. The company markets its products under the Par label primarily to wholesalers, retail drug store chains, managed health care providers, and distributors principally through its internal sales staff. Par Pharmaceutical Companies has research and development agreements with Advancis Pharmaceutical Corporation to develop and market a formulation of the antibiotic amoxicillin; Aveva Drug Delivery Systems, Inc. to market a clonidine transdermal patch, a generic version of Boehringer Ingelheim's Catapres TTS; with IntelliPharmaCeutics, Ltd. for the development of a generic, controlled release drug product for the United States market; and Nortec Development Associates, Inc. The company was formerly known as Pharmaceutical Resources, Inc. and changed its name to Par Pharmaceutical Companies, Inc. in May 2004. Par Pharmaceutical is headquartered in Spring Valley, New York.


Hi-Tech Pharmacal Co., Inc. engages in the manufacture and marketing of prescription, over-the-counter, and nutritional products in liquid and semi-solid dosage forms in the United States. It manufactures generic and branded products, most of which are prescription items and include oral solutions and suspensions, as well as topical creams and ointments. The company also produces liquid ophthalmic, otic, and inhalation products. Hi-Tech Pharmacal markets a line of branded products primarily for people with diabetes, including Diabetic Tussin, a sugar free cough medication; DiabetiDerm, a dermatological product; DiabetiSweet, a sugar substitute for use in baking and cooking; DiabetiTrim, a nutritional shake; and Multi-betic, a multivitamin and mineral supplement. It offers liquid, cream, and ointment pharmaceutical formulations for various disease states, including asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, neurological disorders, and other conditions. The company markets approximately 100 products to chain drug stores, drug wholesalers, managed care organizations, generic distributors, mass merchandisers, hospitals, and mail-order pharmacies. Hi-Tech Pharmacal was founded in 1982 and is based in Amityville, New York.


Isolagen, Inc., a development stage company, engages in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. It develops products primarily for the cosmetic dermatology, cosmetic surgery, periodontal disease, reconstructive dentistry, and other health-related markets. The company's principal product candidate is in Phase III clinical development; and has applications in cosmetic dermatology to correct and reduce the normal effects of aging, such as wrinkles and nasolabial folds. Isolagen's other product candidate is developed to treat periodontal disease, which is in Phase II clinical trial. The company is headquartered in Exton, Pennsylvania.


Mylan Laboratories, Inc. engages in the development, licensing, manufacture, marketing, and distribution of generic and brand pharmaceutical products in the United States. Its Generic segment's pharmaceutical products are therapeutically equivalent to a brand name product and are marketed primarily to wholesalers, retail pharmacy chains, mail order pharmacies, and group purchasing organizations. These products are approved for distribution by the U.S. Food and Drug Administration (FDA) through the Abbreviated New Drug Application process. The company's Brand segment's pharmaceutical products are patent-protected products principally in the therapeutic areas of neurology, dermatology, and cardiology, which are approved by the U.S. FDA through the New Drug Application process. It also includes off-patent brand products, as well as branded generics. This segment markets its products directly to primary care physicians, dermatologists, neurologists, pharmacists, managed care organizations, governmental agencies, independent pharmacies, and chain drug stores. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.


Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction. The company is developing CPP-109, which is based on the chemical compound gamma-vinyl-GABA for the treatment of addiction to cocaine, methamphetamine, and other addictive substances. It also intends to develop CPP-109 to treat other addictions, such as addictions to nicotine, prescription pain medications, alcohol, and marijuana, as well as treatments for obsessive-compulsive disorders, including obesity and compulsive gambling. In addition, Catalyst Pharmaceutical Partners, through a worldwide license agreement with Brookhaven National Laboratory, owns interest primarily in nine patents relating to the right to use vigabatrin to treat various substance addictions. The company was founded in 2002 and is based in Coral Gables, Florida.